Ethno-psychopharmacology

Advances in Current Practice

Edited by

Chee H. Ng
Keh-Ming Lin
Bruce S. Singh
Edmond Y. K. Chiu
Chee Hong Ng dedicates this book to
the memory of Kim Leong Ng for being a lifetime mentor.
Contents

List of figures ix
List of tables x
List of contributors xi
Foreword xiii
Mario Maj
Acknowledgments xv

1 Introduction 1
Isaac Schweitzer

2 Culture and psychopathology 5
Juan E. Mezzich, M. Angeles Ruiperez, and Helena Villa

3 Culture and ethnicity in psychopharmacotherapy 27
Keh-Ming Lin, Chia-Hui Chen, Shu-Han Yu, and Sheng-Chang Wang

4 Ethnic differences in psychotropic drug response and pharmacokinetics 38
Timothy Lambert and Trevor R. Norman

5 Pharmacogenetics of ethnic populations 62
Min-Soo Lee, Rhee-Hun Kang, and Sang-Woo Hahn

6 Variation in psychotropic responses in the Chinese population 87
Tian-Mei Si

7 Variation in psychotropic responses in the Hispanic population 97
Deborah L. Flores and Ricardo Mendoza

8 Identifying inter-ethnic variations in psychotropic response in African Americans and other ethnic minorities 111
William B. Lawson
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Complementary medicines in mental disorders</td>
<td>118</td>
</tr>
<tr>
<td></td>
<td>Xin Yu</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Cultural factors and the use of psychotropic medications</td>
<td>123</td>
</tr>
<tr>
<td></td>
<td>Chee H. Ng and Steven Klimidis</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Outpatient prescribing practices in Asian countries</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>Pichet Udomratn and Chee H. Ng</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Psychiatric inpatient psychotropic prescribing in East Asia</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>Chay-Hoon Tan</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Pharmaco-economic implications for Asia and other economically</td>
<td>151</td>
</tr>
<tr>
<td></td>
<td>disadvantaged countries</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Norman Sartorius</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Integrating theory, practice and economics in psychopharmacology</td>
<td>158</td>
</tr>
<tr>
<td></td>
<td>Keh-Ming Lin, Chun-Yu Chen, Chia-Hui Chen, Jur-Shan Cheng, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sheng-Chang Wang</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Research directions in ethno-psychopharmacology</td>
<td>169</td>
</tr>
<tr>
<td></td>
<td>Chee H. Ng</td>
<td></td>
</tr>
</tbody>
</table>

Index 177
Figures

3.1 Maximal haloperidol concentration after 0.5 mg intramuscular haloperidol  
   page 29
3.2 Factors determining pharmacological response  
   29
10.1 Effect of ethnicity on Medication Attitude Scale total and subscale scores  
   131
12.1 Cost of atypical antipsychotic drugs (clozapine and risperidone) in each country/territory for patients with schizophrenia  
   149
15.1 Cross-ethnic variations in psychopharmacology: influences of genetics, environment, and culture  
   171
Tables

4.1 Some pharmacokinetic studies of antidepressants in different ethnic groups  page 45
4.2 Principal enzymes involved in metabolism of second-generation antipsychotics  49
5.1 Pharmacogenetic studies on the effects of antidepressants  69
5.2 Pharmacogenetic studies on the effects of antipsychotic drugs  73
5.3 Major cytochrome P isoenzymes  75
6.1 The chronology of the development of psychotropics in China  89
10.1 Determinants of attitudes towards psychotropic medications  124
10.2 Factors related to treatment non-adherence  127
11.1 Dosage of haloperidol (mg/day) prescribed by psychiatrists in Southeast and East Asian countries  136
11.2 Time to switching from haloperidol to a second antipsychotic drug  136
11.3 Comparison of antipsychotic prescribing for patients with schizophrenia  138
11.4 Comparison of antipsychotic dosages in CPZe (mean ± SD, range) for patients with schizophrenia only  139
12.1 Percentages of prescription of atypical antipsychotic drugs in each country/territory  146
12.2 Percentages of daily dosages of antipsychotic drugs (mg chlorpromazine equivalent) in each country/territory  146
12.3 Percentages of concurrent psychotropic drugs used in each country/territory for patients with schizophrenia  147
15.1 Development of an international collaborative ethno-psychopharmacology research program  174
Contributors

Chia-Hui CHEN, M.D.
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan

Chun-Yu CHEN, M.S.
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan

Jur-Shan CHENG, Ph.D.
Center for Health Policy Research and Development, National Health Research Institutes, Taiwan

Edmond Y.K. CHIU, A.M., M.B., B.S., D.P.M.
Department of Psychiatry, University of Melbourne, Academic Unit for Psychiatry of Old Age, St George’s Hospital, Victoria, Australia

Deborah L. FLORES, M.D.
David Geffen School of Medicine, Dept. of Psychiatry, Harbor-UCLA Medical Center Torrance, CA, USA

Sang-Woo HAHN
Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea

Rhee-Hun KANG
Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea

Steven KLIMIDIS, Ph.D.
Centre for International Mental Health, School of Population Health, The University of Melbourne, Victoria, Australia

Timothy LAMBERT, B.Sc., M.B., B.S., Ph.D., F.R.A.N.Z.C.P.
Department of Psychological Medicine, University of Sydney, Royal Prince Alfred Hospital, Camperdown NSW, Australia

William B. LAWSON, M.D., Ph.D., F.A.P.A.
Department of Psychiatry, Howard University Hospital, Washington, DC, USA

Min-Soo LEE, M.D., Ph.D.
Department of Psychiatry, Korea University College of Medicine, Seoul, Korea

Keh-Ming LIN, M.D., M.P.H.
Division of Mental Health and Substance Abuse Research, National Health Research Institutes, Taiwan

Mario MAJ, M.D.
Department of Psychiatry, University of Naples, Naples, Italy
Contributors

Ricardo MENDOZA, M.D.
David Geffen School of Psychiatry at UCLA, Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, USA

Juan E. MEZZICH, M.D., Ph.D.
International Center for Mental Health and Division of Psychiatric Epidemiology, Mount Sinai School of Medicine, New York University, New York, USA

Chee H. NG, M.B., B.S., M.Med., M.D.
Department of Psychiatry, The University of Melbourne, St Vincent Hospital & The Melbourne Clinic, Victoria, Australia

Trevor R. NORMAN, B.Sc., Ph.D.
Department of Psychiatry, University of Melbourne, Austin Hospital, Victoria, Australia

M. Angeles RUIPEREZ, Ph.D.
Department of Psychobiology and Basic and Clinical Psychology, Universitat Jaume I. Castelló, Spain

Norman SARTORIUS, M.D., Ph.D.
Geneva, Switzerland

Isaac SCHWEITZER, M.B., B.S., D.P.M., F.R.A.N.Z.C.P., M.D.
Department of Psychiatry, The University of Melbourne, Professorial Unit, The Melbourne Clinic, Victoria, Australia

Tian-Mei SI, M.D., Ph.D.
Institute of Mental Health, Peking University Beijing, China

Bruce S. SINGH, M.B., B.S., Ph.D.
Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia

Chay-Hoon TAN, M.B., B.S., M.Med., Ph.D.
Department of Pharmacology, National University of Singapore, Kent Ridge, Singapore

Pichet UDOMRATN, M.D.
Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

Helena VILLA, Ph.D.
Department of Psychobiology and Basic and Clinical Psychology, Universitat Jaume I. Castelló, Spain

Sheng-Chang WANG, M.D., M.Sc.
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan

Shu-Han YU, M.D.
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan

Xin YU, M.D.
Institute of Mental Health, Peking University Beijing, China
Foreword

This book is very important for two reasons: it is the first-ever textbook of psychopharmacology focusing on the Asia-Pacific region, and it is, as far as I know, the first internationally authored volume dealing specifically with ethno-psychopharmacology.

Both developments are remarkable. In the past few years, the international literature has been enriched by textbooks of psychiatry focusing on Latin America, Asia and Africa, which have proved to be very useful to clinicians in the respective regions, while at the same time providing the international readership with a lot of previously unavailable information. If these textbooks have been useful, even more timely may be this first “regional” textbook of psychopharmacology, which is likely to improve psychiatric practice in the Asia-Pacific region and represent a model for other regions of the world.

On the other hand, a book on ethno-psychopharmacology, which could perhaps have been regarded as a scientific curiosity a decade ago, will certainly not be perceived as such today by the vast majority of psychiatrists worldwide. Most of us live now in multiethnic environments, in which cultural variations in the expression of psychopathology can be directly observed by the average practitioner, and in which problems in communication and diagnostic approach to persons with different ethnic and cultural backgrounds are being experienced on a daily basis. Increasingly widespread also is the awareness of the ethnic and cultural variations in the response to the most common psychotropic medications, which is certainly a matter of genetic polymorphisms, but also a consequence of the impact of a variety of environmental factors.

Nowadays most trials of psychotropic drugs are multicentric, and an increasing number of them are carried out in different regions of the world. However, ethnic variations in response to the tested drugs are rarely a focus of attention in these trials. Moreover, treatment guidelines produced in North America and Europe are often regarded as universally valid, and rarely adapted to other regional contexts. This is still partly due to some reluctance to accept the concept of ethnic variability,
as if it were “politically incorrect.” I have a vivid recollection of what happened not many years ago at an international psychiatric meeting, in which a prominent expert who had briefly mentioned in his presentation the issue of ethnic variation in drug response was subtly accused in the subsequent discussion to be racist. What should be regarded as racist today, instead, is trying to transfer automatically the information acquired in specific areas of the world to all other cultures and ethnicities, even if this implies the use of doses of medications that are inappropriate or of treatment schedules that are not transferable.

This book is a real treasure of information and ideas for research in the field of ethno-psychopharmacology. I think it should be welcomed by clinicians and by researchers in psychiatry and psychopharmacology in all regions of the world. It is unique in the current scientific literature, and is likely to remain as such for many years.

Mario Maj
President Elect, World Psychiatric Association
Acknowledgments

The editors wish to acknowledge the following persons: Christine Hua-Chun Chang and Amy Chia-Hui Lin, secretaries to Keh-Ming Lin; Fiona Kelly, personal assistant to Bruce Singh; and Joy Preston, personal assistant to Edmond Chiu.